12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tolvaptan: Phase III data

Otsuka said it plans to submit regulatory applications for tolvaptan to treat ADPKD in multiple countries, but did not disclose details. Tolvaptan is approved as Samsca in the EU to treat hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in adults. The drug is also approved in the U.S. to treat hypervolemic and euvolemic hyponatremia.

Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan
Product: Tolvaptan...

Read the full 309 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >